MiMedx Brand Guidelines: The Marietta Placental-Tissue Company Behind EPIFIX

A Georgia company that found its business in the placenta.

MiMedx is an American biomedical company based in Marietta, Georgia, in the northern suburbs of Atlanta. Its products are allografts — tissue grafts made from human birth tissue, including the placenta, the amniotic membrane and the umbilical cord — supplied to wound-care and surgical settings. Sources give different founding years: English Wikipedia dates the company to 2008, while the S&P Global company profile carried by StockAnalysis gives 2006.

Its early identity was broader. In December 2010, describing itself as “an integrated developer, manufacturer and marketer of patent protected biomaterial-based products” and quoted on the OTC Bulletin Board, MiMedx announced a definitive agreement to buy Surgical Biologics, a privately held tissue processor in nearby Kennesaw, Georgia, founded in early 2006. The release, reprinted that month by Medical Design and Outsourcing, said Surgical Biologics processed amniotic membrane — the innermost layer of the placenta — donated by mothers with scheduled Caesarean sections and screened under FDA regulations and the standards of the American Association of Tissue Banks.

The release described PURION as Surgical Biologics’ own tissue-processing method; PURION and placental tissue are now at the centre of MiMedx’s business, according to its current company profile. English Wikipedia records the company’s move to the Nasdaq in April 2012 under the ticker MDXG, and its rapid growth in the years that followed: Fortune included MiMedx in its 2017 list of the fastest-growing companies, Wikipedia notes. By 2020 the company had about 710 employees; the S&P profile now lists a little over 800.

EPIFIX, AMNIOFIX and the PURION process.

MiMedx names its products in capitals, and so, increasingly, does it name itself: recent announcements style the company as MIMEDX. The ranges fall into two groups. For wound care, the company’s profile lists sheet and particulate allografts including EPIFIX and EPICORD, as well as newer lines such as EPIEFFECT and CELERA. For surgical use it lists AMNIOFIX, AXIOFILL, HELIOGEN and related products, for settings including lower-extremity repair, plastic surgery, vascular surgery and orthopaedic reconstruction.

The common thread is the process. MiMedx says it processes placental membrane, umbilical cord and the placental disc with its patented PURION method, which combines aseptic processing with terminal sterilisation, and that it sells through a direct sales force, independent agents and distributors in the United States, and that it has a strategic alliance with Vaporox, Inc. to promote that company’s wound-care offerings alongside its own. Many of the product names share the same prefixes — EPI-, AMNIO-, CHORIO- — so the range reads as one family.

Regulation has shaped the business from the start. In 2013, English Wikipedia records, the US Food and Drug Administration examined whether the company’s amniotic products qualified for the lighter regulatory path for human tissue under Section 361 of the Public Health Service Act, and in August of that year said that certain products did not, meaning they would need to meet stricter requirements before sale.

How wound, ostomy and continence brands present themselves.

Wound-care, ostomy and continence companies sell mostly to nurses, surgeons and pharmacists, and their visual language tends to reflect that audience. Brochures and websites in the category often favour soft-focus close-ups of skin and dressings, clean white backgrounds and pale, calm colours, with the product shown in use rather than as an object. Nurses appear again and again: at hospital bedsides, in clinics and in community care, changing a dressing or talking with a patient at home.

Ostomy and continence brands face a different task. Their users live with the products every day, so the imagery usually moves out of the clinic and into ordinary life: discreet lifestyle photography of people with a stoma swimming, hiking, travelling or at work, with the pouch rarely in view. Packaging across the category tends towards pastel tones, plain product names and clear labelling that has to read on a ward shelf and in a home bathroom alike.

The trade also has its own calendar. Companies meet clinicians at congresses such as the conference of the European Wound Management Association (EWMA) in Europe, the Symposium on Advanced Wound Care (SAWC) in the United States and the annual meeting of the Wound, Ostomy and Continence Nurses Society (WOCN), where stands, posters and education sessions carry much of a brand’s presence. Swedish Wikipedia records that Mölnlycke prepared a position document on its Safetac technology together with EWMA.

The companies in this guide range from a Swedish textile mill of 1849 and a Dijon family group to British ostomy specialists and American medical-technology firms. Each guide sets out what can be checked — who founded the company, who owns it and where it says its products are made — and separates documented facts from the company’s own claims.

An accounting case, a relisting and a new chapter.

The company’s recent history includes a serious accounting case, which English Wikipedia sets out with citations to the Wall Street Journal, Bloomberg and US government releases. From 2017, short-sellers publicly accused MiMedx of inflating its sales, and the Securities and Exchange Commission opened an investigation that September; a Justice Department investigation followed in 2018. In June 2018 the company’s top three executives left, and MiMedx said they had been terminated for cause. In November 2018 Nasdaq delisted the shares, which moved to the over-the-counter market, and the company said it would restate its accounts back to 2012.

The outcomes were stated in official actions. In November 2019 MiMedx settled an SEC case over the reporting of its revenue; the same day, federal prosecutors in New York charged two former executives with securities fraud relating to 2015, and both were convicted on one count each in November 2020. In April 2020 the company also settled a Justice Department case under the False Claims Act concerning its pricing disclosures to the Department of Veterans Affairs. A new chief executive arrived in May 2019, most of the senior team was replaced, and after completing its restatement the company returned to Nasdaq on 30 October 2020, English Wikipedia records.

In July 2026 MiMedx announced an agreement to acquire Sanara MedTech, maker of the CellerateRX Surgical collagen powder and BIASURGE surgical irrigation solution; HospiMedica reported in August 2026 that the deal was expected to close by the end of the year, subject to Sanara shareholder approval and regulatory clearance. The companies said the combination would carry MiMedx beyond soft tissue into musculoskeletal work in the operating room, adding Sanara’s exclusive distribution rights to OsStic, a synthetic injectable bone adhesive. The deal had not been completed at the time of writing.

For a design guide, MiMedx shows how a tissue company builds a brand out of a naming system — capitalised product names built on shared prefixes — and how a business rebuilds trust in plain regulatory language after a public crisis. Compare Integra LifeSciences, another American medical-technology company, and Smith+Nephew, the wound-care and medical-technology group. For this guide we use a deep violet, a pale lavender and a soft coral with a sans, an unofficial interpretation; no product or logo is reproduced.

Keep MiMedx’s identity on hand — save it to a board in the Made Good inspiration library.